About Us

ADMA Biologics Completes Acquisition of Biotest Pharmaceuticals Corp (BPC) Therapy Business Unit Assets.

See the Press Release

Who We Are And How We Make An Impact

ADMA Biologics is a biopharmaceutical company relentlessly committed to creating superior products for immunodeficient patients at risk for infection. It is our devotion to this underserved population that fuels us, and our hands-on approach to production and development that sets us apart.

Our Values

Our superior commitment to patients is anchored to our core values:

Human

Human

We make human connection a priority in our products, our patients, and our people.

Courageous

Courageous

We take on the challenges others won't by embracing rare diseases and the underserved populations.

Dynamic

Dynamic

We are relentless in transforming groundbreaking science into meaningful action.

Tenacious

Tenacious

We are tireless in our pursuit of perfection because people's lives are in our hands.

Through our relentless commitment to improving people’s lives, we are changing the future with immunotechnology.

Poised For Growth

Our goal is to be a leader in developing and commercializing specialized, targeted, plasma-derived therapeutics to extend and enhance the lives of individuals who are naturally or medically immunocompromised.

As part of our ongoing commercialization efforts, we plan to hire a small, specialty sales force to market RI-002, if approved, to hospitals, physician offices/clinics, and other specialty treatment organizations. We anticipate staffing additional personnel for patient support, medical affairs, quality assurance, regulatory affairs, scientific affairs, reimbursement, inventory and logistics, human resources, financial and operational management. If and when we receive FDA approval, we may also use a network of national distributors to fulfill orders for RI-002 for use by healthcare professionals and hospitals.

Beyond the present focus on the clinical advancement of RI-002 and expansion of our plasma collection facilities, there are a number of additional opportunities for growth, including:

  • Post RI-002 FDA approval, expand uses in medically appropriate immunocompromised patients
  • Developing additional plasma-derived products through direct R&D and potential licensing opportunities. These follow-on products may include infectious disease specific intravenous immune globulin (IVIG) product candidates targeting immunocompromised PIDD patients as well as transplant patients. Future product candidates could focus on the management of chronic infections (viral and bacterial)

Innovation is in our Blood: Meet our management team

While the members of ADMA Biologics' management team may come from different backgrounds, one thing remains consistent: their innate curiosity and entrepreneurial spirits drive them to ask the tough questions and tackle the unknown.

Adam S. Grossman

Founder, Director, President and Chief Executive Officer

Mr. Grossman has been a director of ADMA since 2007, has served as ADMA's President and Chief Executive Officer since October 2011 and as ADMA's President and Chief Operating Officer between 2007 and October 2011. Mr. Grossman has over 20 years of experience in the blood and plasma industry. Prior to founding ADMA, Mr. Grossman was the Executive Vice President of National Hospital Specialties and GenesisBPS, a position he held between 1994 and 2011. He has experience in launching new products, building and managing national and international sales forces, managing clinical trials, and completing numerous business development transactions. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins, and at the American Red Cross, where he launched new products with the Biomedical Services division.

Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University. Mr. Grossman is the son of Dr. Jerrold B. Grossman, ADMA’s Vice-Chairman. Mr. Grossman was chosen to serve on the Board because, as the Company’s Chief Executive Officer, he is able to provide the Board with critical insight into the day-to-day operations of the Company.

Brian Lenz, CPA

Vice President, Chief Financial Officer

Mr. Lenz joined ADMA as VP, Chief Financial Officer in May 2012. Mr. Lenz was previously at CorMedix Inc., a developmental-stage pharmaceutical and medical device company, where he held the position of Chief Financial Officer from February 2010 and Chief Operating Officer and Chief Financial Officer from January 2012. Prior to joining CorMedix, Mr. Lenz served as Chief Financial Officer of Arno Therapeutics, Inc. from July 2008 to February 2010, Chief Financial Officer of VioQuest Pharmaceuticals, Inc. from April 2004 to June 2008, Controller of Chiral Quest, Inc., a subsidiary of VioQuest Pharmaceuticals, from October 2003 to March 2004, Controller of Smiths Detection from July 2000 to October 2003, and senior auditor at KPMG, LLP from October 1998 to July 2000.

Mr. Lenz received a B.S. from Rider University, an M.B.A. from Saint Joseph's University and is a licensed Certified Public Accountant.

James Mond, M.D., Ph.D.

Chief Scientific and Medical Officer

Dr. Mond joined ADMA as Chief Scientific and Medical Officer in July 2012. Dr. Mond was most recently Chief Scientific Officer and Executive Vice President at Biosynexus, where he was responsible for the preclinical and clinical development of three drug candidates from December 1999 through June 2011. Biosynexus engaged in immunological and non-immunologic approaches to treat or prevent staphylococcus infections. Dr. Mond also functioned as its Chief Medical Officer and had involvement with the U.S. Food and Drug Administration in designing clinical studies. While at Biosynexus Dr. Mond served as Chief Medical Officer for a Phase III clinical trial that was run in 93 neonatal intensive care units in Europe and North America. Prior to that time, he was professor of Medicine, Rheumatology and Immunology at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, actively practicing internal medicine, rheumatology and teaching medical students. Dr. Mond’s lab invented a vaccine technology that was licensed to GlaxoSmithKline and is currently the basis of a number of pediatric vaccines that are commercialized around the world. Dr. Mond also led the laboratory of Immunology at the University and authored 168 papers published in peer reviewed scientific journals and 20 invited articles and book chapters. He has over 20 issued patents in the area of vaccines.

Dr. Mond received his M.D. and Ph.D. from New York University Medical School.

Directed Toward Success: Meet Our Board of Directors

Steven A. Elms

Chairman

Mr. Elms has been a director of ADMA since 2007. He serves as a Managing Partner at Aisling Capital, which he joined in 2000. Previously, Mr. Elms was a Principal in the Life Sciences Investment Banking Group of Hambrecht & Quist. During his 5 years at Hambrecht & Quist, Mr. Elms was involved in over 60 financing and merger and acquisition transactions, helping clients raise in excess of $3.3 billion in capital. Prior to joining Hambrecht & Quist, Mr. Elms traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. His previous healthcare sector experience includes over 2 years as a pharmaceutical sales representative for Marion Laboratories and 2 years as a consultant for The Wilkerson Group.

Mr. Elms received a B.A. in Human Biology from Stanford University and an M.B.A. from Kellogg Graduate School of Management at Northwestern University. Mr. Elms currently serves on the boards of directors of Cidara Therapeutics, Inc., Loxo Oncology, Inc., and Pernix Therapeutics Holdings, Inc. He was chosen to serve on the Board of Directors because of his valuable experience in the investment banking industry, particularly with respect to strategic and financing transactions.

Dr. Jerrold B. Grossman

Founder and Vice Chairman

Dr. Grossman has been a director of ADMA since 2007. He served as the Chief Executive Officer of ADMA, on a part-time basis, between 2007 and 2011. Dr. Grossman is the founder and Chief Executive Officer of National Hospital Specialties, a specialty plasma derivatives distribution business, and has served as Chief Executive Officer of that company since 1980. Additionally, Dr. Grossman is the founder and President of GenesisBPS, a medical device firm specializing in blood collection and processing equipment, and has served as President of that company since 1990. Previously, Dr. Grossman has held positions at the New York Blood Center and Immuno-U.S., Inc. and served as the Chairman of the Board of Bergen Community Blood Services. Currently, Dr. Grossman is a member of the New Jersey Blood Bank Task Force, and a founder and director of the New Jersey Association of Blood Bank Professionals. Dr. Grossman is a founder and director of Pascack Bancorp, Inc. and is currently a member of its audit committee. He has also provided consulting services to various government agencies and international organizations.

Dr. Grossman received a B.A. in Economics and Finance from Fairleigh Dickinson University, an M.B.A. from Fairleigh Dickinson University, and his Doctorate in Business Management from Pace University. Dr. Grossman is the father of Adam S. Grossman, ADMA's President and Chief Executive Officer. He was chosen to serve on the Board of Directors because of his role as founder and past Chief Executive Officer of ADMA, as well as his more than 35 years of experience serving a variety of companies and associations in the blood and plasma industry.

Adam S. Grossman

Founder, Director, President and Chief Executive Officer

Mr. Grossman has been a director of ADMA since 2007, has served as ADMA's President and Chief Executive Officer since October 2011 and as ADMA's President and Chief Operating Officer between 2007 and October 2011. Mr. Grossman has over 20 years of experience in the blood and plasma industry. Prior to founding ADMA, Mr. Grossman was the Executive Vice President of National Hospital Specialties and GenesisBPS, a position he held between 1994 and 2011. He has experience in launching new products, building and managing national and international sales forces, managing clinical trials, and completing numerous business development transactions. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins, and at the American Red Cross, where he launched new products with the Biomedical Services division.

Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University. Mr. Grossman is the son of Dr. Jerrold B. Grossman, ADMA’s Vice-Chairman. Mr. Grossman was chosen to serve on the Board because, as the Company’s Chief Executive Officer, he is able to provide the Board with critical insight into the day-to-day operations of the Company.

Bryant E. Fong

Director

Mr. Fong, who became a director of ADMA in May 2012, has over 19 years of experience in the life sciences industry. Mr. Fong is a founding Managing Director at Biomark Capital Fund, a life sciences private equity firm formed in 2013. Prior to BioMark Capital, Mr. Fong was a Managing Director and General Partner at Burrill & Company, where he spent almost 16 years investing in and managing investments in private and public companies in the biotechnology industry. Some of Mr. Fong's most notable investments include Pharmasset (VRUS), Novadaq Technologies (NVDQ), Galapagos (GLPG), Ceptaris Therapeutics, and Ferrokin Biosciences. In addition, Mr. Fong has played key roles in the formation of a number of portfolio companies, including serving as Nora Therapeutic's first president and founder and initial CEO of i2Dx.

Prior to joining Burrill & Company, Mr. Fong held positions as a research scientist with 2 early stage biotechnology companies located in the San Francisco Bay Area. Mr. Fong currently serves on the Boards of Directors of a number of private life science companies.

Mr. Fong earned his B.S. with honors in Molecular and Cell Biology-Biochemistry from the University of California, Berkeley. He was chosen by Biomark Capital to serve on the ADMA's Board of Directors because of his extensive experience in the biotechnology industry.

Dov A. Goldstein, M.D.

Director

Dr. Goldstein has been a director of ADMA since 2007. He was employed as a principal at Aisling Capital from 2006 to 2008 and partner from 2008 through October 2017. Dr. Goldstein served as the Chief Financial Officer of Loxo Oncology, Inc. between July 2014 and January 2015, and has been its acting Chief Financial Officer since January 2015. From 2000 to 2005, Dr. Goldstein served as Chief Financial Officer of Vicuron Pharmaceuticals, Inc., which was acquired by Pfizer, Inc. in September 2005. Prior to joining Vicuron, Dr. Goldstein was Director of Venture Analysis at HealthCare Ventures. He also completed an internship in the Department of Medicine at Columbia-Presbyterian Hospital. Dr. Goldstein serves as a director of Cempra, Inc. and Esperion Therapeutics, Inc. and Loxo Oncology, Inc.

Dr. Goldstein received a B.S. from Stanford University, an M.B.A. from Columbia Business School and received his M.D. from Yale School of Medicine. ADMA believes that Dr. Goldstein's medical training and his experience in the biopharmaceutical industry as a venture capital investor, as an executive of Vicuron and a member of the Boards of Directors of other biopharmaceutical companies, as well as his valuable perspective on ADMA's business, give him the qualifications and skills to serve as a director.

Lawrence P. Guiheen

Director

Mr. Guiheen, who became a director of ADMA in July 2012, has over 25 years of experience in the blood and plasma industry. Since July 2013 Mr. Guiheen has been Chief Commercial Officer of Kedrion BioPharma,Inc., based in Barga, Italy and Fort Lee, New Jersey. Kedrion markets therapies globally for hemophilia, hemolytic disease of the newborn, immune and neurological disorders.

Prior to July 2013, Mr. Guiheen was principal of Guiheen and Associates, a consulting group that specializes in biopharmaceutical, pharmaceutical and medical device commercialization. Before July 2011, Mr. Guiheen was with Baxter Healthcare Corporation for over 30 years. Most recently he held the positions of General Manager Global Hemophilia Franchise (from December 2010), President of Global BioPharmaceuticals for Baxter Healthcare's BioScience Division (March 2010 - December 2010) and President of BioPharmaceuticals US (January 2004 - March 2010).

Mr. Guiheen had been a member of the BioScience Senior Management Team for over 14 years and has extensive experience leading global and domestic commercial organizations in the plasma and recombinant therapies. Mr. Guiheen is past Chairman of the Global Board of Directors for the Plasma Proteins Therapeutics Association (PPTA) and a past member of the Board of Directors of California Healthcare Institute (CHI).

Mr. Guiheen holds a B.A. degree in business administration from Rutgers University. Mr. Guiheen was chosen to serve on the Board of Directors because of his extensive experience in the plasma and pharmaceutical industries.

Eric I. Richman

Director

Mr. Richman has been a director of ADMA since 2007. Mr. Richman served as the President and Chief Executive Officer of PharmAthene, Inc. between October 2010 and March 2015. Mr. Richman served as the President and interim Chief Executive Officer of PharmAthene between May and October 2010, as President and Chief Operating Officer between March and May 2010 and as Senior Vice President, Business Development and Strategic Planning between August 2003 and March 2010. He has also served on PharmAthene's Board of Directors since May 2010.

Prior to joining PharmAthene, Mr. Richman held various commercial and strategic positions of increasing responsibility over a 12 year period at MedImmune, Inc. from its inception and was Director, International Commercialization at that company. Mr. Richman served as director of Lev Pharmaceuticals and Chairman of its Commercialization Committee and served as a director of American Bank.  

Mr. Richman received a Bachelor of Biomedical Science from the Sophie Davis School of Biomedical Education and a M.B.A. from the American Graduate School of International Management. He was chosen to serve on the Board of Directors because of his experience in the development and commercialization of plasma derived products and experience as an executive officer of PharmAthene.

Bernhard Ehmer

Director

Mr. Ehmer has served as the chairman of the board of management of Biotest since January 2015. Prior to joining Biotest, from 2008 to 2012, Mr. Ehmer served as the president of ImClone Systems Corporation, a wholly owned subsidiary of Eli Lilly and Company, in the United States, and as a managing director of ImClone Systems International in Germany, respectively. From 2007 to 2008, Mr. Ehmer served as the chief executive officer of Fresenius Biotech in Germany. From 2000 until 2005, Mr. Ehmer headed the Business Area Oncology of Merck KgaA, Darmstadt (“Merck KGaA”). From 1998 until 2000, Mr. Ehmer was the head of "Global Clinical Operations" at Merck KGaA. Between 1986 and 1998, Mr. Ehmer held various functions at Boehringer Mannheim in Germany, Italy and Singapore.

Mr. Ehmer holds a degree in medicine and worked in Internal Medicine at the Academic Teaching Hospital of the University of Heidelberg with a focus on Cardiology/Intensive Care until he joined the pharmaceutical industry in 1986.

Curiosity Combined with Innovation: Meet Our Scientific Advisory Board

Jean-Laurent Casanova, M.D, Ph.D., is a professor and Head of Laboratory at the Rockefeller University, Senior Attending Physician at the Rockefeller University Hospital and Investigator at the Howard Hughes Medical Institute. He is a pediatrician and immunologist by training, and in practice, has become an internationally renowned human geneticist investigating infectious diseases. Dr. Casanova discovered that life-threatening infectious diseases from childhood may be caused by single-gene inborn errors of immunity.

Dr. Casanova was an international research scholar with the Howard Hughes Medical Institute from 2005 to 2008 and was elected to the European Molecular Biology Organization in 2005. He has also received numerous awards throughout his career, including the Professor Lucien Dautrebande Pathophysiology Foundation Prize (2004), Richard Lounsbery Award (2008), E. Mead Johnson Award from the Society for Pediatric Research (2010), InBev-Baillet Latour Health Prize (2011), Ilse & Helmut Wachter Foundation Award and the Milstein Award (2012), Robert Koch Prize and the Sanofi-Institut Pasteur Award (2014) and was elected as a Foreign Associate of the National Academy of Sciences of the USA (2015).

Roy F. Chemaly, M.D., M.P.H., is a professor in the department of infectious diseases, infection control and employee health, division of internal medicine at The University of Texas, MD Anderson Cancer Center. Dr. Chemaly is board certified, specializing in infectious diseases, and has published extensively on infections in immunocompromised hosts such as stem cell transplant patients. He is also the director of Infection Control and Antimicrobial Stewardship Programs.

John DeVincenzo, M.D., is a practicing pediatric infectious disease specialist, Professor of Pediatrics and Professor of Microbiology, Immunology, and Biochemistry at the University of Tennessee School of Medicine. His research focuses on understanding the pathogenesis of Respiratory Syncytial Virus (RSV) directly in children and using this understanding to develop therapeutic and prevention strategies against this virus. He is the author of over 140 original published abstracts and papers on this subject. Dr. DeVincenzo has conducted numerous clinical trials in children defining the role of prevention and therapeutic applications of monoclonal antibodies targeting RSV in infants and the immunosuppressed.

Jordan S. Orange, M.D., Ph.D., is the chief of immunology, allergy, and rheumatology, professor and section head for immunology, allergy and rheumatology in the department of pediatrics at Baylor College of Medicine, and the director of the Center for Human Immunobiology at Texas Children's Hospital. Dr. Orange is a board-certified pediatrician and allergist/immunologist with a clinical specialty in primary immunodeficiency disease. Dr. Orange has focused his research efforts upon Primary Immunodeficiency, Immunoglobulin, NK cell deficiency and the cell biology of human NK cell defenses.

E. Richard Stiehm, M.D., is a distinguished research professor of pediatrics emeritus at the University of California, Los Angeles. Dr. Stiehm served as Chief of the Division of Pediatric Immunology/Allergy/Rheumatology from 1969 to 2003 and a graduate of the University of Wisconsin and its Medical School. Dr. Stiehm has been the training director for over 50 fellows in allergy and immunology and his research interests include primary immunodeficiency, neonatal immunology, immunoglobulin therapy, pediatric rheumatology and pediatric HIV infection.

He is the author of over 500 articles and chapters and is the chief editor of Immunologic Disorders in Infants and Children editions I through V and an editor of Stiehm's Immunodeficiency (in press).